Chemosensitizing effects of methyl jasmonate on paclitaxel-resistant androgen-dependent and independent prostate cancer cell lines

The taxane-based therapy provides survival benefit in patients with metastatic prostate cancer; however, the average is less than 20 months due to partial taxane-related chemoresistance. Innovative strategies are needed overcome chemoresistance for improved patient survival. In this project, paclitaxel-resistance was developed on androgen-independent PC3 and androgen-dependent 22Rv1 LNCaP human cancer (PCa) cell lines investigate efficacy of methyl jasmonate (MeJa), an anti-cancer drug, overcoming PCa were maintained RPMI-1640 medium supplemented 10% fetal bovine serum (FBS) at 37?C under 5% CO2. exposed gradually increasing doses paclitaxel. Since resistance could not be achieved, study continued line. It demonstrated that paclitaxel-resistant overexpress ABCB1. Resistance levels cells MeJa activity all resistant parental measured using CellTiter-Glo? luminescent assay. Test results compared Student?s t-test or analysis variance (ANOVA). P?0.05 (two-tailed) considered significant. conclusion, showed more cytotoxicity paclitaxel (PC3-PtxR) (22Rv1-PtxR) cells. Detection cytotoxic effects may contribute development alternative new compounds prevention chemosensitization chemotherapeutics such as